Newsbenzinga
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
· Published
Article summary
Johnson & Johnson released positive Phase 2b and Phase 3 trial results for its Rybrevant lung cancer treatment combinations.
An excerpt from the original article.
Comments —
Loading comments…